COMMUNIQUÉS West-GlobeNewswire

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy [...]
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026
TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- CoreHealth Technologies Inc. today announced that Michael Peters will conclude his tenure as Chief Executive Officer at the end of June, following five years of leadership that [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
23/06/2026
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as [...]
Integra LifeSciences Announces Key Executive Appointments
23/06/2026
Leadership appointments reinforce company’s commitment to enhancing commercial execution and deepening customer engagement, while building leadership depth PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra [...]
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
23/06/2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics [...]
Persephone Biosciences’ Science-Backed Infant and Toddler Synbiotics Now Available on Amazon
23/06/2026
- Clinically researched synbiotics developed from findings published in Cell Host & Microbe and Communications Biology now available through Amazon, with TikTok Shop expansion planned next month - - Prime Day [...]
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
23/06/2026
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM [...]
ApolloMD Welcomes 2026 Emergency Medicine Administrative Fellows and Opens Applications for Next Class
23/06/2026
ATLANTA, June 23, 2026 (GLOBE NEWSWIRE) -- ApolloMD proudly welcomes Nishant Gogna, DO, and Eun Sung “Kevin” Kim, MD, as the incoming physicians for its Emergency Medicine Administrative Fellowship program. ApolloMD [...]
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
23/06/2026
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics. Dr. Houston's deep experience with protein [...]
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
23/06/2026
Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ [...]
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Premier Health of America Announces CCAA Proceedings
23/06/2026
MONTREAL, June 23, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) announces proceedings under the Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) [...]
Advanced Rehabilitation, LLC Expands iKNOT Curriculum to Address Complex Regional Pain Syndrome & Chronic Upper Extremity Problems
23/06/2026
CHARLOTTE, N.C., June 23, 2026 (GLOBE NEWSWIRE) -- Advanced Rehabilitation, LLC today announced the expansion of its educational platform featuring the integrated Kinetic Neuro-Ortho Training (iKNOT) approach. The [...]
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
23/06/2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...]
Transactions in connection with share buy-back program
23/06/2026
Company announcement no. 22 - 26 23 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]

Pages